Iron Chelating Properties of Eltrombopag: Investigating Its Role in Thalassemia-induced Osteoporosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Dec 4

PMID 30507954

Citations 20

Authors

Francesca Punzo

Chiara Tortora

Maura Argenziano

Maddalena Casale

Silverio Perrotta

Francesca Rossi

Affiliations

Soon will be listed here.

Abstract

Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron chelator that prevents transfusion related iron overload complications. Recently Eltrombopag (ELT) iron chelating properties are emerging. ELT is an agonist at Thrombopoietin receptor, used in treatment of thrombocytopenia. We tested ELT and Deferasirox in iron overloaded osteoclasts from thalassemic patients and donors measuring intracellular iron, TRAP expression and osteoclast activity. We confirmed ELT iron chelation capacity also in bone tissue and a synergic effect when used with Deferasirox. Moreover, having demonstrated its effects on osteoclast activity, we suggest for the first time that ELT could ameliorate bone tissue's health reducing bone mass loss.

Citing Articles

Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.

Di Paola A, Marrapodi M, Di Martino M, Giliberti G, Di Feo G, Rana D Int J Mol Sci. 2024; 25(5).

PMID: 38474150 PMC: 10932404. DOI: 10.3390/ijms25052902.

Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology.

Giordano P, Lassandro G, Barone A, Cesaro S, Fotzi I, Giona F Front Med (Lausanne). 2023; 10:1214308.

PMID: 37521342 PMC: 10375288. DOI: 10.3389/fmed.2023.1214308.

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review.

Marrapodi M, Mascolo A, Roberti D, Di Martino M, Rafaniello C, Riccardi C Front Pediatr. 2023; 11:1149718.

PMID: 37168802 PMC: 10166202. DOI: 10.3389/fped.2023.1149718.

CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy.

Argenziano M, Pota V, Di Paola A, Tortora C, Marrapodi M, Giliberti G Int J Mol Sci. 2023; 24(4).

PMID: 36834757 PMC: 9964283. DOI: 10.3390/ijms24043345.

Emerging Roles of the Iron Chelators in Inflammation.

Di Paola A, Tortora C, Argenziano M, Marrapodi M, Rossi F Int J Mol Sci. 2022; 23(14).

PMID: 35887336 PMC: 9318075. DOI: 10.3390/ijms23147977.

References

Aydinok Y, Kattamis A, Cappellini M, El-Beshlawy A, Origa R, Elalfy M . Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015; 125(25):3868-77. PMC: 4490296. DOI: 10.1182/blood-2014-07-586677. View

Lambert M, Witmer C, Kwiatkowski J . Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am J Hematol. 2017; 92(6):E88-E91. DOI: 10.1002/ajh.24705. View

Dede A, Trovas G, Chronopoulos E, Triantafyllopoulos I, Dontas I, Papaioannou N . Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporos Int. 2016; 27(12):3409-3425. DOI: 10.1007/s00198-016-3719-z. View

Taccone-Gallucci M, Manca-di-Villahermosa S, Noce A . Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011; 364(15):1476-7. DOI: 10.1056/NEJMc1101838. View

Daher R, Karim Z . Iron metabolism: State of the art. Transfus Clin Biol. 2017; 24(3):115-119. DOI: 10.1016/j.tracli.2017.06.015. View

Vlachodimitropoulou E, Chen Y, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M . Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 2017; 130(17):1923-1933. PMC: 6558288. DOI: 10.1182/blood-2016-10-740241. View

Rumi M, Di Marco V, Colombo M . Management of HCV-Related Liver Disease in Hemophilia and Thalassemia. Semin Liver Dis. 2018; 38(2):112-120. DOI: 10.1055/s-0038-1655774. View

Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt V . Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis. 2017; 9(1):e2017019. PMC: 5333732. DOI: 10.4084/MJHID.2017.019. View

Valenti L, Varenna M, Fracanzani A, Rossi V, Fargion S, Sinigaglia L . Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2008; 20(4):549-55. DOI: 10.1007/s00198-008-0701-4. View

10.

Burness C, Keating G, Garnock-Jones K . Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia. Drugs. 2016; 76(8):869-78. DOI: 10.1007/s40265-016-0581-4. View

11.

Fibach E, Rachmilewitz E . Iron overload in hematological disorders. Presse Med. 2017; 46(12 Pt 2):e296-e305. DOI: 10.1016/j.lpm.2017.10.007. View

12.

Dev S, Babitt J . Overview of iron metabolism in health and disease. Hemodial Int. 2017; 21 Suppl 1:S6-S20. PMC: 5977983. DOI: 10.1111/hdi.12542. View

13.

Rossi F, Perrotta S, Bellini G, Luongo L, Tortora C, Siniscalco D . Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica. 2014; 99(12):1876-84. PMC: 4258755. DOI: 10.3324/haematol.2014.104463. View

14.

Poggiali E, Cassinerio E, Zanaboni L, Cappellini M . An update on iron chelation therapy. Blood Transfus. 2012; 10(4):411-22. PMC: 3496216. DOI: 10.2450/2012.0008-12. View

15.

Kontoghiorghes G . The aim of iron chelation therapy in thalassaemia. Eur J Haematol. 2017; 99(5):465-466. DOI: 10.1111/ejh.12939. View

16.

Wong R, Saleh M, Khelif A, Salama A, Portella M, Burgess P . Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23):2527-2536. DOI: 10.1182/blood-2017-04-748707. View

17.

Lu M, Lin T, Chiang P, Kuo P, Wang N, Wu W . Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major. Ther Drug Monit. 2017; 39(2):185-191. DOI: 10.1097/FTD.0000000000000378. View

18.

Taher A, Saliba A . Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):265-271. PMC: 6142532. DOI: 10.1182/asheducation-2017.1.265. View

19.

Goodnough L, Panigrahi A . Blood Transfusion Therapy. Med Clin North Am. 2017; 101(2):431-447. PMC: 7094649. DOI: 10.1016/j.mcna.2016.09.012. View

20.

Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A . Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol. 2014; 89(12):1102-6. DOI: 10.1002/ajh.23844. View